Professor James CH Yang, MD, PhD

Professor James CH Yang, MD, PhD

Professor, Graduate Institute of Oncology 
National Taiwan University 
Director, Department of Oncology 
National Taiwan University Hospital 
Taipei, Taiwan

Related Videos

In the setting of lung cancer, what is the advantage of using whole exome NGS versus targeted gene testing? Why do you advocate comprehensive molecular profiling? Video

In the setting of lung cancer, what is the advantage of using whole exome NGS versus targeted gene testing? Why do you advocate comprehensive molecular profiling?

In the setting of lung cancer, what is the advantage of using whole exome NGS versus targeted gene testing? Why do you advocate comprehensive molecular profiling?

What is the importance of ROS-1 fusion mutations? What are the therapeutic implications of their detection? Video

What is the importance of ROS-1 fusion mutations? What are the therapeutic implications of their detection?

What is the importance of ROS-1 fusion mutations? What are the therapeutic implications of their detection?

What is the importance of ALK fusion mutations? What are the therapeutic implications of detection? How effective are second-generation ALK inhibitors? What does the data show as far as PFS? Video

What is the importance of ALK fusion mutations? What are the therapeutic implications of detection? How effective are second-generation ALK inhibitors? What does the data show as far as PFS?

What is the importance of ALK fusion mutations? What are the therapeutic implications of their detection? How effective are the second-generation ALK inhibitors? What does the data show as far as PFS?

What are the most important activating EGFR mutations and what are the specific implications of their detection? And what if these patients relapse on a TKI? Video

What are the most important activating EGFR mutations and what are the specific implications of their detection? And what if these patients relapse on a TKI?

What are the most important activating EGFR mutations and what are the specific implications of their detection? And what if these patients relapse on a TKI?

What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful? Video

What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?

What do we know about the rationale for employing NGS-based whole exome profiling in NSCLC patients who have progressed to metastatic disease on chemotherapy? Is molecular profiling at this stage of the disease useful?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy? Video

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

Can you be specific about how NGS-based signatures in metastatic lung cancer can provide actionable roadmaps for targeted therapy?

What is the comprehensive spectrum of molecular alterations that whole exome NGS provides that are integral to precision-based treatment for lung adenocarcinoma? Video

What is the comprehensive spectrum of molecular alterations that whole exome NGS provides that are integral to precision-based treatment for lung adenocarcinoma?

What is the comprehensive spectrum of molecular alterations that whole exome NGS provides that are integral to precision-based treatment for lung adenocarcinoma?